Aristotle University Of Thessaloniki (AUTH)
Επίδραση του ζολεδρονικού οξέος σε οστικές μεταστάσεις πρωτοπαθούς καρκίνου του πνεύμονα
Abstract
dc:descriptionIntroduction: Recent studies have documented the efficacy of the administration of bisphosphonates in the treatment of bone metastases in patients with lung cancer. aim: The study aims to investigate the potential benefit of zoledronic acid (ZOL) in lung cancer patients with regard to bone alterations. Method: 160 patients with stage IIIB-IV, small cell or non-small cell lung Ca type, with or without bone metastases participated in the study. Patients were divided into 4 groups of 40 each as follows: 1st group: patients with bone metastases treated with ZOL, 2nd group: patients with bone metastases not treated with ZOL, 3rd group: patients without bone metastases treated with ZOL, 4th group: patients without bone metastases not treated with ZOL. The 1st and 3rd group received 4 mg i.v. ZOL in a dose at a rate of over 15 minutes, initially every 28 days during chemotherapy, and at the end of chemotherapy every 21 days as a maintenance treatment. All patients were screened to measure osteoprotein, osteocalcin, RANK and RANKL values. Results: ZOL administration is associated with a reduced risk of new bone metastases in patients with and without bone metastases history (1st and 3rd group) compared with patients not receiving ZOL (2nd and 4th group). In patients receiving ZOL, a decrease in RANKL was recorded, whereas opposite behavior (increase) was observed in patients who did not receive ZOL. Reverse findings were found for osteoprotegerin and osteocalcin. conclusions: The findings of the study confirmed the efficacy of treatment of lung cancer with zoledronic acid in reducing the incidence and reducing the risk of bone metastases in these patients.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tremmas, Ioannis
- Τρέμμας, Ιωάννης
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44319